- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| LYELL IMMUNOPHARMA Aktie jetzt für 0€ handeln | |||||
| 12:30 | BofA reiterates Lyell Immunopharma stock Underperform on rival exit | - | Investing.com | ||
| 23.03. | H.C. Wainwright reiterates Lyell Immunopharma stock rating at buy | 3 | Investing.com | ||
| 16.03. | Lyell Immunopharma: Citizens bestätigt "Market Outperform" nach Fortschritten in Studien | 1 | Investing.com Deutsch | ||
| 16.03. | Citizens reiterates Lyell Immunopharma stock rating on trial progress | 1 | Investing.com | ||
| 12.03. | Lyell Immunopharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 12.03. | Lyell Immunopharma, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 09.03. | Lyell Immunopharma closes $50M equity tranche, names new CFO | 1 | Investing.com | ||
| 09.03. | Lyell Immunopharma, Inc: Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer | 1 | GlobeNewswire (USA) | ||
| 09.03. | Lyell Immunopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.03. | Citizens initiates Lyell Immunopharma stock at outperform, $34 target | 1 | Investing.com | ||
| 12.02. | Lyell Immunopharma, Inc: Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma | 1.062 | GlobeNewswire (Europe) | PiNACLE - H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator's choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell... ► Artikel lesen | |
| 22.12.25 | Lyell Immunopharma pops on recent ASH data, immunotherapy expansion | 4 | Seeking Alpha | ||
| 07.12.25 | Lyell Immunopharma, Inc: Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition | 2 | GlobeNewswire (USA) | ||
| 05.12.25 | Lyell Immunopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11.25 | Lyell Immunopharma reports Q3 results | 3 | Seeking Alpha | ||
| 12.11.25 | Lyell Immunopharma, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 10.11.25 | Lyell Immunopharma buys exclusive global rights to colorectal cancer drug | 1 | Seeking Alpha | ||
| 10.11.25 | Lyell Immunopharma, Inc: Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer | 198 | GlobeNewswire (Europe) | LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal... ► Artikel lesen | |
| 10.11.25 | Lyell Immunopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.11.25 | Lyell Immunopharma: Vielversprechende Daten zu dualer CAR-T-Zelltherapie bei Lymphomen | 1 | Investing.com Deutsch |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,020 | -11,40 % | Medigene: Zurückziehung - 18.11.2025 | ||
| AMGEN | 295,45 | +0,14 % | Amgen hebt Jahresprognose an - Quartalszahlen etwa wie erwartet | THOUSAND OAKS (dpa-AFX) - Der US-Biotechkonzern Amgen blickt trotz zunehmender Konkurrenz zuversichtlicher auf das laufende Jahr. 2026 werde der Umsatz bei 37,1 bis 38,5 Milliarden Dollar liegen, teilte... ► Artikel lesen | |
| BIOGEN | 160,74 | -0,36 % | Aktien New York Ausblick: Wenig Bewegung vor Zinsentscheid und Tech-Zahlen | NEW YORK (dpa-AFX) - An den US-Börsen zeichnet sich zur Wochenmitte eine uneinheitliche, aber insgesamt wenig bewegte Eröffnung ab. Im Fokus stehen die erst nach Börsenschluss angekündigten Quartalszahlen... ► Artikel lesen | |
| EDITAS MEDICINE | 2,510 | -1,95 % | Editas Medicine stellt präklinische Daten zur LDL-senkenden Therapie EDIT-401 vor | ||
| GALAPAGOS NV | 24,120 | +0,42 % | Galapagos NV: Galapagos' Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders' Meetings 2026 | Mechelen, Belgium; April 28, 2026, 22:01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all resolutions proposed at the Company's Annual and Extraordinary Shareholders' Meetings (AGM... ► Artikel lesen | |
| IMMATICS | 9,460 | +1,07 % | TD Cowen initiates Immatics stock coverage with buy rating | ||
| AUTOLUS THERAPEUTICS | 1,230 | +1,65 % | Autolus Therapeutics plc: Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction | Initiative focused on driving gross profit margin and path to profitability for the ALL businessCompany will reduce headcount by approximately 13% while doubling manufacturing of products for commercial... ► Artikel lesen | |
| TANGO THERAPEUTICS | 21,530 | 0,00 % | Stifel raises Tango Therapeutics stock price target on drug combo potential | ||
| TSCAN THERAPEUTICS | 1,180 | +2,61 % | TScan Therapeutics, Inc.: TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting | ||
| QIAGEN | 29,035 | +1,84 % | Qiagen senkt Jahresprognose: QuantiFERON belastet, Aktie im Minus | Qiagen hat im ersten Quartal 2026 vorläufigen Zahlen zufolge einen Umsatz von 492 Millionen Dollar erzielt, ein Plus von 2 Prozent auf berichteter Basis, bei konstanten Wechselkursen jedoch ein Minus... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 30,960 | 0,00 % | Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs | - CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) expected in H1 2026 -
- Phase 1 healthy adult trial... ► Artikel lesen | |
| AVALYN PHARMA | 29,015 | 0,00 % | Avalyn Pharma Prices Upsized $300 Mln IPO At $18 Per Share | WASHINGTON (dpa-AFX) - Avalyn Pharma Inc. (AVLN), a clinical-stage biopharmaceutical company, announced the pricing of its upsized initial public offering of 16.67 million shares at a price... ► Artikel lesen | |
| ALUMIS | 24,690 | 0,00 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen | |
| BIONTECH | 88,20 | +0,06 % | BioNTech vor Wendepunkt: Diese Zahlen entscheiden jetzt | BioNTech steht nach dem Rückgang des Corona-Geschäfts vor einem strategischen Umbruch und richtet seinen Fokus zunehmend auf die Onkologie. Investoren blicken gespannt auf kommende Quartalszahlen und... ► Artikel lesen | |
| ERASCA | 10,640 | 0,00 % | Erasca, Inc.: Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L... ► Artikel lesen |
Das Unternehmen LYELL IMMUNOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 19,760 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LYELL IMMUNOPHARMA INC finden Sie auf Wallstreet Online.